Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contacts | Login 
  Users Online: 334 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents  
Year : 2016  |  Volume : 6  |  Issue : 1  |  Page : 17-27

Phenotypic detection and molecular characterization of beta-lactamase genes among Citrobacter species in a tertiary care hospital

1 Department of Microbiology, AIIMS, Bhubaneshwar, Odisha, India
2 Department of Microbiology, Armed Forces Medical College, Pune, Maharashtra, India

Date of Web Publication8-Jan-2016

Correspondence Address:
Atul Khajuria
Department of Microbiology, Armed Forces Medical College, Pune - 411 040, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2231-0770.173578

Rights and Permissions

Objective: To examine the distribution, emergence, and spread of genes encoding beta-lactamase resistance in Citrobacter species isolated from hospitalized patients in a tertiary care hospital. Methods: A prospective study was conducted in a 1000-bed tertiary care center in Pune, India from October 2010 to October 2013. A total of 221 Citrobacter spp. isolates were recovered from clinical specimens from different patients (one isolate per patient) admitted to the surgical ward, medical ward and medical and surgical Intensive Care Units. Polymerase chain reaction (PCR) assays and sequencing were used to determine the presence of beta-lactamase encoding genes. Conjugation experiments were performed to determine their transferability. Isolate relatedness were determined by repetitive element based-PCR, enterobacterial repetitive intergenic consensus-PCR and randomly amplified polymorphic DNA. Results: Among 221 tested isolates of Citrobacter spp. recovered from various clinical specimens, 179 (80.9%) isolates showed minimum inhibitory concentration (MIC) >4 μg/ml against meropenem and imipenem. One hundred and forty-five isolates with increased MICs value against carbapenems were further processed for molecular characterization of beta-lactamase genes. Susceptibility profiling of the isolates indicated that 100% retained susceptibility to colistin. Conjugation experiments indicated that blaNDM-1was transferable via a plasmid. Conclusion: The ease of NDM-1 plasmid transmissibility may help their dissemination among the Citrobacter species as well as to others in Enterobacteriaceae. Early detection, antimicrobial stewardship and adequate infection control measures will help in limiting the spread of these organisms.

Keywords: blaNDM-1, blaVIM-2, combined-disc synergy test, Citrobacter freundii, Citrobacter koseri, double-disc synergy tests, metallo-beta-lactamase, modified Hodge test

How to cite this article:
Praharaj AK, Khajuria A, Kumar M, Grover N. Phenotypic detection and molecular characterization of beta-lactamase genes among Citrobacter species in a tertiary care hospital. Avicenna J Med 2016;6:17-27

How to cite this URL:
Praharaj AK, Khajuria A, Kumar M, Grover N. Phenotypic detection and molecular characterization of beta-lactamase genes among Citrobacter species in a tertiary care hospital. Avicenna J Med [serial online] 2016 [cited 2021 Jan 21];6:17-27. Available from: https://www.avicennajmed.com/text.asp?2016/6/1/17/173578

   Introduction Top

Citrobacter species are an important cause of nosocomial infections, particularly involving the urinary and respiratory tracts of hospitalized patients and are inhabitants of the human gastrointestinal tract, often found in human feces and hospital environment.[1],[2] In recent years, Citrobacter species have been commonly isolated from various clinical specimens such as urine, pus, and blood. A significant increase in nosocomial infections caused by Citrobacter species has been reported, especially in Neonatal Intensive Care Units (NICUs).[3],[4],[5] It has been reported to cause neonatal sepsis, brain abscess, urinary tract infections (UTIs), bloodstream infections, skin and surgical site infections, burns infections, intra-abdominal sepsis, meningitis, and pneumonia.[3],[4],[5] Fatality in Citrobacter septicemia ranges from 33% to 48%[6] Infant survivors may have significant damage to the central nervous system, including profound mental retardation, seizures, and hemiparesis.[7] There is very little data dealing with Citrobacter isolates in India: Neither its antibiotic sensitivity pattern nor the molecular characterization of its resistance genes. This study focused on determining the antibiotic resistance pattern and prevalence of metallo-beta-lactamase (MBL) genes in carbapenem-resistant Citrobacter spp. isolated in a tertiary care center.

   Materials and Methods Top

The bacterial isolates

A prospective study was conducted in a 1000-bed tertiary care center in Pune, India from October 2010 to October 2013. A total of 221 Citrobacter spp. isolates were recovered from clinical specimens of hospitalized patients admitted to the medical and surgical ICUs. Samples were collected from patients, using strict aseptic precautions and in accordance with standard protocols [8] and immediately processed without delay. The isolates were obtained from various clinical specimens such as urine, blood, pus, respiratory secretions (sputum, endotracheal secretions, broncho-alveolar lavage (BAL), and bronchial wash), and other sterile body fluids. Bacterial identification was performed by routine conventional microbial culture and biochemical tests using standard recommended techniques.[8] The organism was identified up to the species level using VITEK-GNI cards (bioMérieux, Marcy l'Etoile, France).

Antimicrobial susceptibility testing

The antimicrobial susceptibility test was performed by the Kirby-Bauer disc diffusion technique on Mueller-Hinton agar, as per Clinical Laboratory Standard Institute (CLSI) guidelines.[9] The antibiotics tested were as follows (potency in μg/disc): Ampicillin (10), cefuroxime (30), cefpodoxime (CPD) (30), ceftazidime (30), cefepime (30), cefotaxime (30), piperacillin (100), ticarcillin (75), piperacillin-tazobactam (100/10), ticarcillin-clavulanic acid (75/10), aztreonam (30), imipenem (IP) (10), meropenem (10), ertapenem (10), colistin (10), gentamicin (10), tobramycin (10), amikacin (30), netilmicin (30), ciprofloxacin (5), levofloxacin (5), lomefloxacin (10), and ofloxacin (5) (Hi-Media Laboratories Pvt., Ltd., Mumbai, India). Pseudomonas aeruginosa ATCC 27853,  Escherichia More Details coli ATCC 25922, E. coli ATCC 35218 and Klebsiella pneumoniae ATCC 700603 were used as quality control strains.

Minimum inhibitory concentration determination

Minimum inhibitory concentrations (MICs) of antibiotics were determined by VITEK-2 AST-GN25 and AST-GN280 susceptibility cards in accordance with the CLSI recommendations and manufacturer's instructions, except that the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for tigecycline and colistin.[9],[10] MICs were further determined by the E-test (bioMérieux, Marcy l'Etoile, France).

Phenotypic screening for carbapenemase production

Isolates with reduced susceptibility to meropenem and IP (diameter of zones of inhibition ≤13 mm) by disc diffusion method and showed higher MICs as determined by the E-test were further screened for the production of carbapenemase. The phenotypic detection of the carbapenemase production was performed by the modified Hodge test (MHT) using ertapenem and meropenem discs (10 μg) for each isolate as per CLSI guidelines.[9] For MHT K. pneumoniae ATCC BAA-1705 and BAA-1706 were used as positive and negative controls, respectively. MBL production detected by double-disc synergy tests (DDST) with both IP and meropenem discs (10 ug) plus ethelenediaminetetraacetic acid (EDTA) (750 ug) for all the carbapenem resistant isolates, as described earlier by Lee et al. and combined-disc synergy test (CDST) as described previously by Franklin et al. using IP and meropenem discs (10 μg) and 0.1 M EDTA (292 μg).[11],[12]K. pneumoniae ATCC BAA-2146 and P. aeruginosa ATCC 27853 were used as positive and negative controls, respectively. MBL (IP/IP-inhibitor [IPI]) E-test was carried out to detect MBL as per manufacturer's instructions.

DNA extraction and molecular detection

DNA was extracted from the bacterial isolates using the spin column method (QIAGEN; GmbH, Hilden, Germany) as per manufacturer's instructions. Polymerase chain reaction (PCR)-based detection of beta-lactamase (extended-spectrum beta-lactamase [ESBL]) genes (blaCTXM, blaSHV, blaTEM and blaOXA), Ambler class B MBLs (blaIMP, blaVIM, blaSPM, blaGIM, blaSIM and blaNDM-1), Ambler class D (blaOXA-23, blaOXA-24 and blaOXA48) and serine carbapenemases (blaKPC, blaGES and blaNMC) were carried out on the isolates using Gene Amp 9700 PCR System (Applied Biosystems, Singapore).[13],[14],[15],[16] PCR products were run on 1.5% agarose gel, stained with ethidium bromide visualized under ultraviolet light and photographed. The amplicons were purified using QIAquick PCR purification kit (QIAGEN; GmbH, Hilden, Germany).

DNA sequencing and sequence analysis

Automated sequencing was performed on an ABI 3730XL DNA analyzer using the Big Dye system (Applied Biosystems Foster City, CA, USA). Sequences were compared with known sequences using the BLAST facility (http://blast.ncbi.nlm.nih.gov).

Conjugation experiments

Transfer of resistance genes by conjugation was assayed by mating experiments in Luria-Bertani broth using the clinical Citrobacter isolates (parental strains) as donors and an azide-resistant E. coli J53 as the recipient strain using 1:10 ratio. The transconjugants were selected on Luria-Bertani agar with selection based on growth on agar in the presence of ceftazidime (30 µg/ml) and sodium azide (100 µg/ml).[16] Plasmids were separated and compared by co-electrophoresis with plasmid of known sizes from E. coli (V517 and 39R861) on a horizontal 0.5% agarose gel at 50 volts for 3 h. Bands were visualized with UV transilluminator after staining with 0.05% ethidium bromide.

Strain molecular typing

Repetitive element based-PCR (REP-PCR), enterobacterial repetitive intergenic consensus (ERIC-PCR) and randomly amplified polymorphic DNA (RAPD) assays were performed to characterize Citrobacter spp. recovered from patients.[17],[18]

Plasmid analysis

Plasmids from each parental strain and its transconjugants were extracted by using Qiagen plasmid mini kit (GmbH, Hilden, Germany) as per manufacturer's Instructions. Extracted plasmid DNA were subjected to plasmid-based replicon incompatibility (Inc.) typing by using eighteen pairs of primers to perform five multiplex and three single PCRs which recognized F, FIA, FIB, FIC, B/O, X, Y, N, P, W, T, A/C, HI1, HI2, I1-Ic, L/M, K, and FII replicons as described previously.[19] Plasmid replicons were determined for the ESBL and carbapenemase-producing clinical isolates.

   Results Top

A total of 221 Citrobacter spp. isolates were recovered from clinical specimens from different patients (one isolate per patient) admitted to the surgical ward, medicinal ward and medical and surgical ICUs of a tertiary care center. Distribution of Citrobacter spp. isolates from various samples is shown in [Figure 1] and [Table 1].
Figure 1: Distribution of Citrobacter spp. from various sites of infection

Click here to view
Table 1: The distribution of carbapenem resistant Citrobacter spp. from total isolated

Click here to view

The largest proportion of specimens were from UTI (98 or 44%), followed by 19% (43) in skin and soft tissue infections (SSTIs), 13% (29) in blood stream infections (BSIs), 14% (30) in Intra-abdominal infections (IAIs) and miscellaneous and 10% (21) in Respiratory tract infections (RTIs), respectively. Among 221 tested isolates, 179 (80.9%) isolates showed MIC >4 µg/ml against IP and meropenem. The majority of Carbapenem-resistant Citrobacter spp. were from urine 48% (87), followed by 21% (37) in wound swabs and pus, 12% (21) in IAIs and miscellaneous, 11% (20) in blood and endo-tracheal aspirate (09), BAL (05) both together constitute 08% (14), respectively [Table 1].

One hundred and ninety-eight out of 221 isolates, showed resistance to penicillins and third generation cephalosporins by the disc diffusion method, among them 179 (80.99%) were found to exhibit reduced susceptibility to IP and meropenem (diameter of zones of inhibition ≤15 mm) and 145 were found to have MIC values for IP, meropenem and ertapenem ranging from 8 to 32 µg/ml as per CLSI breakpoints. All the 221 isolates were found to be susceptible to colistin while (167/221) 75.56% were susceptible to tigecycline in vitro as per EUCAST MIC breakpoints. Of 221 isolates, 179 were found carbapenem-resistant as MICs was >4 µg/ml against IP and meropenem as determined by the E-test and VITEK-2, MHT for carbapenemase production was positive for 34.84% (77), DDST in 51.58% (114), CDST in 50.67% (112) isolates and MBL (IP/IPI) E-test was positive for 58.37% (129) isolates. Results of different phenotypic tests of Citrobacter spp. recovered from various clinical specimens are shown in [Table 2] and [Table 3].
Table 2: Percentage and result of different phenotypic tests of C. freundii recovered from various infection sites

Click here to view
Table 3: Percentage and result of different phenotypic tests of C. koseri recovered from various infection sites

Click here to view

In these phenotypic tests from different infection sites among 130 Citrobacter freundii tested, carbapenem resistance was detected in 82.30% (107) isolates. MBL E-test was found positive for 78.64% (81), followed by CDST in 54.6% (71), DDST in 53.8% (70), and MHT in 39.2% (51) [Table 2]. Among 91 Citrobacter koseri tested, carbapenem resistance was detected in 79.1% (72) isolates MBL E-test found positive for 52.74% (48) isolates, followed by CDST in 47.3% (43), DDST in 46.15% (42) and MHT in 28.57% (26) [Table 3].

Of 221 isolates, 179 (80.99%) were found to exhibit reduced susceptibility to IP and meropenem and were ESBL producers and among them 145 were found to have MIC values for IP, meropenem, and ertapenem ranging from 8 to 32 µg/ml as per CLSI breakpoints. The presence of blaNDM-1 was detected in 55.30% (99/179) while blaVIM was present in 17.87% (32/179) of carbapenem-resistant strains. Based on Automated sequencing the genes were characterized and known sequences were compared using the BLAST facility (http://blast.ncbi.nlm.nih.gov). The sequences of blaNDM-1 from C. freundii and C. koseri determined in this study have been assigned GenBank accession no. KR816561 and KR816562.

From UTIs, a single NDM-1 gene was present in 26 C. freundii isolates. NDM-1, TEM-1 and CTXM-15 altogether were found in 13 isolates while SHV, CTXM-15, and NDM-1 gene were present in 15 isolates. SHV, CTXM-15 and VIM-2 gene were present in 12 isolates whereas VIM-2, TEM-1, and CTXM-15 were found in 10 isolates.

In C. koseri, a single NDM-1 gene was present in 21 isolates, NDM-1, TEM-1, SHV, and CTXM-15 together were found in 18 isolates while CTXM-15 and NDM-1 gene were present in 18 isolates. VIM-2, CTXM-15, and TEM-1 altogether were present in 03 isolates [Figure 2].
Figure 2: Distribution of beta-lactamase genes in Citrobacter spp. isolated from urine

Click here to view

From BSIs, NDM-1, SHV, TEM-1, and CTXM-15 were found in 5 C. freundii isolates while VIM-2, TEM-1, SHV, and CTXM-15 were altogether detected in 3 isolates whereas In C. koseri NDM-1 along with TEM-1, CTXM-15, and SHV genes was present in 03 isolates [Figure 3].
Figure 3: Distribution of beta-lactamase genes in Citrobacter spp. isolated from blood stream infections

Click here to view

From RTIs, NDM-1, CTXM-15, SHV, and TEM-1, genes altogether were present in 06 C. freundii isolates while one isolate had the co-presence of VIM-2, TEM-1, CTXM-15, and SHV-12 gene. In C. koseri co-presence of NDM-1, TEM-1, CTXM-15, and SHV genes was detected in 03 isolates [Figure 4].
Figure 4: Distribution of beta-lactamase genes in Citrobacter spp. isolated from respiratory tract infections

Click here to view

From SSTIs, C. freundii NDM-1, CTXM-15, TEM-1, and SHV genes altogether were present in 11 isolates, while copresence of VIM-2, CTXM-15, TEM-1, and SHV gene were detected in 5 isolates, 08 isolates, 05 isolates with VIM-2 also had and 05 isolates with also had CTXM-15 whereas in C. koseri NDM-1, SHV, TEM-1, and CTXM-15 genes were present in 7 isolates while copresence of VIM-2, CTXM-15, and TEM-1 was detected in 3 isolates [Figure 5].
Figure 5: Distribution of beta-lactamase genes in Citrobacter spp. isolated from skin and soft tissue infections

Click here to view

From IAIs and miscellaneous in C. freundii NDM-1, CTXM-15, TEM-1, and SHV altogether were present in 8 isolates while VIM-2, CTXM-15. Moreover, TEM-1 were detected in 02 isolates whereas in C. koseri 6 isolates had co presence of NDM-1, SHV, CTXM-15, and TEM-1 genes [Figure 6].
Figure 6: Distribution of beta-lactamase genes in Citrobacter spp. isolated from intra-abdominal infections and miscellaneous culture

Click here to view

Strain molecular typing

Genotypic analysis by molecular typing of 81 strains of C. freundii (MBL producers) using RAPD PCR produced an average of 14–18 fragments per C. freundii strains. There were all together 10 RAPD pattern assigned as CF-A to CF-J [Figure 7].
Figure 7: Randomly amplified polymorphic DNA polymerase chain reaction banding pattern among 10 clonal clusters of C. freundii

Click here to view

As per ERIC PCR and REP PCR banding pattern, the isolates showed a genotypic diversity with 08 clonal clusters exhibited by 81 isolates. Genotypic analysis using REP PCR produced an average of 6–8 fragments per C. freundii strains [Figure 8].
Figure 8: Repetitive element based-polymerase chain reaction banding pattern among 8 clonal cluster of Citrobacter freundii

Click here to view

Genotypic analysis by molecular typing of 48 strains of C. koseri using RAPD PCR produced an average of 10–12 fragments per C. koseri strains. There were all together 6 RAPD pattern assigned as CK-A to CK-F [Figure 9].
Figure 9: Randomly amplified polymorphic DNA polymerase chain reaction banding pattern among 6 clonal clusters of Citrobacter koseri

Click here to view

As per ERIC PCR and REP PCR banding pattern, 06 clonal clusters were exhibited by 48 isolates (MBL producers). Genotypic analysis using ERIC PCR produced an average of 12–18 fragments per C. koseri strains [Figure 10].
Figure 10: Enterobacterial repetitive intergenic consensus-polymerase chain reaction banding pattern among 6 clonal cluster of Citrobacter koseri

Click here to view

RAPD PCR distinguishes the various clones from one another better than REP PCR and ERIC PCR [Figure 7],[Figure 8],[Figure 9],[Figure 10]. In molecular strain typing RAPD types distributed between various REP and ERIC types.

Plasmid replicon typing, transferability and conjugation studies

Conjugation experiments revealed that blaNDM-1 was transferable via a plasmid along with other beta-lactamase genes carried on other plasmids. Plasmid profiling of the isolates showed that blaNDM-1 was carried on plasmids ranging in sizes from 35 to 130 kb and blaVIM was carried on 50 to 200 kb size plasmids. All of the plasmid types were transferable. From UTI 50% (n = 20), SSTIs, BSIs, RTIs and IAIs and others 50% (N = 23) of multidrug resistant C. freundii were randomly selected as a donor Citrobacter spp. strains for conjugation studies and plasmid typing [Table 4].
Table 4: Transferability of MBL and ESBL gene present along with plasmid typing of C. freundii isolates

Click here to view

From SSTIs, BSIs, UTIs, RTIs, and IAIs and others 50% (N = 24) of multidrug resistant C. koseri were randomly selected as a donor Citrobacter spp. strains for conjugation studies and plasmid typing [Table 5].
Table 5: Transferability of MBL and ESBL gene present along with plasmid typing of C. koseri isolates

Click here to view

MIC values for IP, meropenem and ertapenem among transconjugants are ranging from 8 to 32 µg/ml as per CLSI breakpoints. Both bla TEM-1 and bla SHV were associated with Inc. FIA, Inc. FIB, Inc. FIC multiple replicons. The blaNDM-1 gene was located on Inc. A/C, Inc. FII and Inc. N plasmids. BlaVIM-2 was carried on plasmids belonging to Inc. FII replicons, Inc. B/O replicons and Inc. nreplicons. Majority of bla CTX-M-15 was associated with multiple replicons either (Inc. FIA, Inc. FIB) OR (Inc. FIIB, Inc. FIB) type [Table 4] and [Table 5].

   Discussion Top

Citrobacter is an opportunistic pathogen causing outbreaks where there are local or systemic breaches to host defenses. Common infections caused by Citrobacter spp. are UTI, bacteremia, meningitis, pneumonia, osteomyelitis, peritonitis, and endocarditis.[3],[6],[7],[20],[21],[22],[23],[24],[25] It has been a cause of neonatal sepsis,[4],[5],[6],[7] and IAI.[26]Citrobacter bacteremia is associated with a high mortality rate between 33% and 48%.[6],[7],[27]C. freundii and C. koseri are the two most common pathogens and infections can be acquired from exogenous as well as endogenous sources, being ubiquitous in nature as a saprophyte in soil and sewage and as a commensal in human gastrointestinal tract.

In our study, carbapenem-resistant C. freundii was the most prominent species isolated 59.78% (107/179) followed by C. koseri 40.22% (72/179) and our finding [Table 1] were similar to others as reported earlier.[28],[29] These isolates showed a high level of resistance to the beta-lactam antibiotics as well as to the beta-lactam/beta-lactamase inhibitor combination which were tested in the study. Sixty-five percentage (145/221) isolates were found to be multi drug resistant, the resistance being to penicillins, cephalosporins, fluoroquinolones, and aminoglycosides using disc diffusion method. The majority of specimens were from urine 44%, followed by SSTI 19%, Drain tip, tissue, other body fluids, and miscellaneous culture constitute 14%, blood 13% and respiratory secretions 10%, respectively.[25],[30] CPD resistance can be used as a phenotypic marker for ESBL detection in cases of UTI. The worldwide prevalence of ESBLs available at PubMed in Citrobacter spp. was reported to be 0.5–36%.[31],[32] In our study, 80.9% (179/221) of Citrobacter isolates were ESBL producers and this study correlates well with another study by Khanna et al. from India.[25]BlaCTX-M-15 was the only CTX-M reported in our study while others have reported blaCTX-M-35, blaCTX-M-30,blaCTX-M-14blaCTX-M-9 and blaCTX-M-3 from USA,[33] Canada,[34] China,[35] UK,[36] France,[37] Poland,[38] Korea,[39] and Spain.[40] There are very few studies in Medical literature, regarding MBL detection among Citrobacter spp. in India and abroad as compared to other members of family Enterobacteriaceae. In our study, 58.37% (129/221) of Citrobacter, were producing MBL genes. A study from Kolkata, India [41] have reported 41.67% of MBL production among Citrobacter spp. [Table 2] and [Table 3]. Their lower frequency might be due to the sample size and geographical region or to timing of the studies as the prevalence of these resistance genes in increasing with time.[30],[41] Emergence of blaNDM-1 producing Citrobacter isolates reported from Bangladesh,[42] Turkey,[43] Thailand,[44] France,[45] South Africa,[46] United Arab Emirates,[47] Canada,[48],[49] and India.[50] We detected presence of blaNDM-1 in 55.30% (99/179) while blaVIM was present in 17.87% (32/179) of carbapenem resistant strains. The presence of blaIMP[51],[52] and blaGIM[53] has been reported in Citrobacter isolates in other countries, but we did not find any of these MBL in our study. Likewise, we found no blaKPC-2 and blaKPC-3 as has been reported in Citrobacter spp. by Deshpande et al.[54] and Mavroidi et al.[55] PBRT of purified plasmids from the clinical isolates of Citrobacter spp. revealed Inc. N, Inc. A/C and Inc. FII type plasmids associated with NDM-1 carriage which correlates well with previous studies.[47],[48],[50] Carriage of NDM-1 has also been reported on plasmid Inc. HII, Inc. X-type and Inc. L/M.[47],[48],[50],[51],[52] Inc. FII, Inc. B/O and Inc. N replicon type plasmids were associated with blaVIM carriage suggesting that MBL genes are carried on multiple plasmids. RAPD PCR was better as compared to REP PCR and ERIC PCR [Figure 7],[Figure 8],[Figure 9],[Figure 10]. This study has shown that the MBL genes are transmissible by conjugation, which suggests that the presence of plasmid-borne MBL genes among the organisms making up the gut flora may facilitate transmission of resistance genes from one organism to another.

   Conclusion Top

A high prevalence of carbapenem resistance was reported among Citrobacter isolates investigated in this study. This indicates spread of NDM-1 producing Citrobacter in central India. Early detection is important as the simultaneous presence of other resistance genes makes the organisms refractory to most of the common antibiotics used in clinical practice. Furthermore, the presence of these genes on plasmids that are transmissible to other species. Thus, the detection of genes for carbapenem resistance should be a major focus of infection control to prevent transmission of MBL genes to other patients and to other bacterial species within the same patient.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Washington WC Jr, Allen SD, Janda WM, Koneman EW, Gary PW, Schreckenberger PC, et al. The Enterobacteriaceae. Color Atlas and Textbook of Diagnostic Microbiology. 6th ed., Ch. 6. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 211-302.  Back to cited text no. 1
Abbott SL. Klebsiella, Enterobacter, Citrobacter, Serratia, Plesiomonas, and Other Enterobacteriaceae. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Landry ML, editors. Manual of Clinical Microbiology. 9th ed. New York: ASM Press; 2007. p. 698-715.  Back to cited text no. 2
Holmes B, Aucken HM. Citrobacter, Enterobacter, Klebsiella, Serratia and other members of the Enterobacteriaceae. In: Collier L, Balows A, Sussman M, editors. Microbiology and Microbial Infections: Systematic Bacteriology. 9th ed. London: Arnold; 1998. p. 999-1033.  Back to cited text no. 3
Khadka SB, Thapa B, Mahat K. Nosocomial Citrobacter infection in neonatal intensive care unit in a hospital of Nepal. J Nepal Paediatr Soc 2010;31:105-9.  Back to cited text no. 4
Thapa B, Tribuddharat C. Molecular characterization of Citrobacter freundii isolated from neonates in Neonatal Intensive Care Unit of Nepal. J Nepal Paediatr Soc 2012;32:132-5.  Back to cited text no. 5
Pepperell C, Kus JV, Gardam MA, Humar A, Burrows LL. Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother 2002;46:3555-60.  Back to cited text no. 6
Doran TI. The role of Citrobacter in clinical disease of children: Review. Clin Infect Dis 1999;28:384-94.  Back to cited text no. 7
Collee JG, Miles RS, Wan B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. Edinburgh: Churchill Livingstone; 1996. p. 131-50.  Back to cited text no. 8
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty Second Informational Supplement M100-S22. Wayne, PA, USA: CLSI; 2012.  Back to cited text no. 9
European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for Interpretation of MICs and Zone Diameters (Version 2); 2012. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCASTfiles/Breakpointtables/Breakpointtablev2.0120221.pdf. [Last accessed on 2014 Feb 23].  Back to cited text no. 10
Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003;41:4623-9.  Back to cited text no. 11
Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol 2006;44:3139-44.  Back to cited text no. 12
Oliver A, Weigel LM, Rasheed JK, McGowan JE Jr, Raney P, Tenover FC. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 2002;46:3829-36.  Back to cited text no. 13
Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-ß-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother 2013;68:550-3.  Back to cited text no. 14
Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: The phantom menace. J Antimicrob Chemother 2012;67:1597-606.  Back to cited text no. 15
Hong SS, Kim K, Huh JY, Jung B, Kang MS, Hong SG. Multiplex PCR for rapid detection of genes encoding class A carbapenemases. Ann Lab Med 2012;32:359-61.  Back to cited text no. 16
Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991;19:6823-31.  Back to cited text no. 17
Vogel L, Jones G, Triep S, Koek A, Dijkshoorn L. RAPD typing of Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens and Pseudomonas aeruginosa isolates using standardized reagents. Clin Microbiol Infect 1999;5:270-6.  Back to cited text no. 18
Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 2005;63:219-28.  Back to cited text no. 19
Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001;33:947-53.  Back to cited text no. 20
Lipsky BA, Hook EW 3rd, Smith AA, Plorde JJ. Citrobacter infections in humans: Experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 1980;2:746-60.  Back to cited text no. 21
Kline MW. Citrobacter meningitis and brain abscess in infancy: Epidemiology, pathogenesis, and treatment. J Pediatr 1988;113:430-4.  Back to cited text no. 22
Gupta N, Yadav A, Choudhary U, Arora DR. Citrobacter bacteremia in a tertiary care hospital. Scand J Infect Dis 2003;35:765-8.  Back to cited text no. 23
Drelichman V, Band JD. Bacteremias due to Citrobacter diversus and Citrobacter freundii. Incidence, risk factors, and clinical outcome. Arch Intern Med 1985;145:1808-10.  Back to cited text no. 24
Khanna A, Singh N, Aggarwa AI, Khanna M. The antibiotic resistance pattern in Citrobacter species: An emerging nossocomial pathogen in a tertiary care hospital. J Clin Diagn Res 2012;6:642-4.  Back to cited text no. 25
Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Bacteremia due to Citrobacter species: Significance of primary intraabdominal infection. Clin Infect Dis 1996;23:543-9.  Back to cited text no. 26
Kanamori H, Yano H, Hirakata Y, Endo S, Arai K, Ogawa M, et al. High prevalence of extended-spectrum ß-lactamases and qnr determinants in Citrobacter species from Japan: Dissemination of CTX-M-2. J Antimicrob Chemother 2011;66:2255-62.  Back to cited text no. 27
Khorasani G, Salehifar E, Eslami G. Profile of microorganisms and antimicrobial resistance at a tertiary care referral burn centre in Iran: Emergence of Citrobacter freundii as a common microorganism. Burns 2008;34:947-52.  Back to cited text no. 28
Samonis G, Karageorgopoulos DE, Kofteridis DP, Matthaiou DK, Sidiropoulou V, Maraki S, et al. Citrobacter infections in a general hospital: Characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2009;28:61-8.  Back to cited text no. 29
Mohanty S, Singhal R, Sood S, Dhawan B, Kapil A, Das BK. Citrobacter infections in a tertiary care hospital in Northern India. J Infect 2007;54:58-64.  Back to cited text no. 30
Fernandes R, Amador P, Oliveira C, Prudêncio C. Molecular characterization of ESBL-producing Enterobacteriaceae in northern Portugal. ScientificWorldJournal 2014;2014:782897.  Back to cited text no. 31
Ali AM, Rafi S, Qureshi AH. Frequency of extended spectrum beta lactamase producing gram negative bacilli among clinical isolates at clinical laboratories of Army Medical College, Rawalpindi. J Ayub Med Coll Abbottabad 2004;16:35-7.  Back to cited text no. 32
Tian GB, Adams-Haduch JM, Qureshi ZA, Wang HN, Doi Y. CTX-M-35 extended-spectrum beta-lactamase conferring ceftazidime resistance in Citrobacter koseri. Int J Antimicrob Agents 2010;35:412-3.  Back to cited text no. 33
Abdalhamid B, Pitout JD, Moland ES, Hanson ND. Community-onset disease caused by Citrobacter freundii producing a novel CTX-M beta-lactamase, CTX-M-30, in Canada. Antimicrob Agents Chemother 2004;48:4435-7.  Back to cited text no. 34
Zhang R, Yang L, Cai JC, Zhou HW, Chen GX. High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression. J Med Microbiol 2008;57(Pt 3):332-7.  Back to cited text no. 35
Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK. J Antimicrob Chemother 2004;54:628-33.  Back to cited text no. 36
Lartigue MF, Fortineau N, Nordmann P. Spread of novel expanded-spectrum beta-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France. Clin Microbiol Infect 2005;11:588-91.  Back to cited text no. 37
Baraniak A, Fiett J, Sulikowska A, Hryniewicz W, Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum beta- lactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2002;46:151-9.  Back to cited text no. 38
Kim J, Lim YM. Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp. and Serratia marcescens in Korea: Dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 2005;43:2452-5.  Back to cited text no. 39
Miró E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, et al. Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005;56:1152-5.  Back to cited text no. 40
Kumar S, Bandyopadhyay M, Mondal S, Pal N, Ghosh T, Bandyopadhyay M, et al. Tigecycline activity against metallo-ß-lactamase-producing bacteria. Avicenna J Med 2013;3:92-6.  Back to cited text no. 41
[PUBMED]  Medknow Journal  
Islam MA, Talukdar PK, Hoque A, Huq M, Nabi A, Ahmed D, et al. Emergence of multidrug-resistant NDM-1-producing gram-negative bacteria in Bangladesh. Eur J Clin Microbiol Infect Dis 2012;31:2593-600.  Back to cited text no. 42
Yanik K, Emir D, Eroglu C, Karadag A, Güney AK, Günaydin M. Investigation of the presence of New Delhi metallo-beta-lactamase-1 (NDM-1) by PCR in carbapenem-resistant gram-negative isolates. Mikrobiyol Bul 2013;47:382-4.  Back to cited text no. 43
Rimrang B, Chanawong A, Lulitanond A, Wilailuckana C, Charoensri N, Sribenjalux P, et al. Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand. J Antimicrob Chemother 2012;67:2626-30.  Back to cited text no. 44
Denis C, Poirel L, Carricajo A, Grattard F, Fascia P, Verhoeven P, et al. Nosocomial transmission of NDM-1-producing Escherichia coli within a non-endemic area in France. Clin Microbiol Infect 2012;18:E128-30.  Back to cited text no. 45
Rubin JE, Peirano G, Peer AK, Govind CN, Pitout JD. NDM-1-producing Enterobacteriaceae from South Africa: Moving towards endemicity? Diagn Microbiol Infect Dis 2014;79:378-80.  Back to cited text no. 46
Sonnevend A, Al Baloushi A, Ghazawi A, Hashmey R, Girgis S, Hamadeh MB, et al. Emergence and spread of NDM-1 producer Enterobacteriaceae with contribution of IncX3 plasmids in the United Arab Emirates. J Med Microbiol 2013;62(Pt 7):1044-50.  Back to cited text no. 47
Peirano G, Ahmed-Bentley J, Fuller J, Rubin JE, Pitout JD. Travel-related carbapenemase-producing gram-negative bacteria in Alberta, Canada: The first 3 years. J Clin Microbiol 2014;52:1575-81.  Back to cited text no. 48
Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol 2012;50:3877-80.  Back to cited text no. 49
Poirel L, Ros A, Carricajo A, Berthelot P, Pozzetto B, Bernabeu S, et al. Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India. Antimicrob Agents Chemother 2011;55:447-8.  Back to cited text no. 50
Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-beta-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: Prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Antimicrob Chemother 2002;50:503-11.  Back to cited text no. 51
Hawkey PM, Xiong J, Ye H, Li H, M'Zali FH. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001;194:53-7.  Back to cited text no. 52
Wendel AF, Brodner AH, Wydra S, Ressina S, Henrich B, Pfeffer K, et al. Genetic characterization and emergence of the metallo-ß-lactamase GIM-1 in Pseudomonas spp. and Enterobacteriaceae during a long-term outbreak. Antimicrob Agents Chemother 2013;57:5162-5.  Back to cited text no. 53
Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006;12:223-30.  Back to cited text no. 54
Mavroidi A, Neonakis I, Liakopoulos A, Papaioannou A, Ntala M, Tryposkiadis F, et al. Detection of Citrobacter koseri carrying beta-lactamase KPC-2 in a hospitalised patient, Greece, July 2011. Euro Surveill 2011;16. pii: 19990.  Back to cited text no. 55


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10]

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]

This article has been cited by
1 Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades
Ahmed Babiker,Daniel R. Evans,Marissa P. Griffith,Christi L. McElheny,Mohamed Hassan,Lloyd G. Clarke,Roberta T. Mettus,Lee H. Harrison,Yohei Doi,Ryan K. Shields,Daria Van Tyne,Daniel J. Diekema
Journal of Clinical Microbiology. 2020; 58(9)
[Pubmed] | [DOI]
2 Clinical characteristics of Citrobacter meningitis in adults: High incidence in patients with a postneurosurgical state and strains not susceptible to third-generation cephalosporins
Chia-Yi Lien,Jun-Jun Lee,Chun-Chih Chien,Chi-Ren Huang,Cheng-Hsien Lu,Wen-Neng Chang
Journal of Clinical Neuroscience. 2018;
[Pubmed] | [DOI]
3 Antimicrobial Resistance and Cytotoxicity of Citrobacter spp. in Maanshan Anhui Province, China
Liyun Liu,Ruiting Lan,Liqin Liu,Yonglu Wang,Yushi Zhang,Yiting Wang,Jianguo Xu
Frontiers in Microbiology. 2017; 8
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded458    
    Comments [Add]    
    Cited by others 3    

Recommend this journal